Remission Doubled With Risankizumab vs Ustekinumab in CD

Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a "once in a career" result, study authors say.
Medscape Medical News

source https://www.medscape.com/viewarticle/997377?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?